Table 1. Baseline characteristics.
| Baseline characteristics | N |
|---|---|
| Number of patients | 11 |
| Median age, years (range) | 45 [36-65] |
| Median ECOG PS (range) | 1 (0-2) |
| Gender | |
| Male | 10 |
| Female | 1 |
| Median lines of prior therapy | 2 [1-5] |
| Prior high dose Imatinib | 8 |
| Prior sunitinib | 5 |
| Prior everolimus | 2 |
| Sites of disease | |
| Primary site | |
| Gastric | 6 |
| Small bowel | 4 |
| Retroperitoneal | 1 |
| Metastatic site | |
| Liver | 6 |
| Nodes | 6 |
| Peritoneal | 5 |
| Lung | 1 |
| Prior surgery | |
| Yes | 7 |
| No | 4 |
| Mutation status | |
| c-kit | |
| Exon 11 | 3 |
| Exon 9 | 1 |
| Exon 17 | 1 |
| PDGFRA | |
| Exon 18 | 2 |
| Exon 12 | 1 |
| Uninterpretable | 3 |
| Unavailable | 1 |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; PDGFRA, platelet derived growth factor receptor alpha.